Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Microbiol. 2008 Jul;6(7):529-40. doi: 10.1038/nrmicro1927.

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Author information

1
Department of Molecular Medicine, Rochester, MayoClinic, Minnesota 55905, USA. Cattaneo.Roberto@mayo.edu

Abstract

Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

PMID:
18552863
PMCID:
PMC3947522
DOI:
10.1038/nrmicro1927
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center